Your browser is no longer supported. Please, upgrade your browser.
Tempest Therapeutics Inc.
Index- P/E- EPS (ttm)-24.99 Insider Own1.10% Shs Outstand0.93M Perf Week-3.77%
Market Cap101.56M Forward P/E- EPS next Y-4.80 Insider Trans0.00% Shs Float- Perf Month-0.82%
Income-26.10M PEG- EPS next Q-1.09 Inst Own27.40% Short Float- Perf Quarter-8.49%
Sales- P/S- EPS this Y40.60% Inst Trans247.40% Short Ratio0.06 Perf Half Y-55.50%
Book/sh51.99 P/B0.28 EPS next Y35.50% ROA-52.40% Target Price- Perf Year-36.60%
Cash/sh- P/C- EPS next 5Y- ROE-72.00% 52W Range10.39 - 41.55 Perf YTD-54.67%
Dividend- P/FCF- EPS past 5Y45.60% ROI- 52W High-64.98% Beta0.49
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low40.11% ATR1.07
Employees12 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)48.31 Volatility8.24% 7.08%
OptionableYes Debt/Eq0.00 EPS Q/Q9.50% Profit Margin- Rel Volume0.01 Prev Close15.11
ShortableYes LT Debt/Eq0.31 Earnings- Payout- Avg Volume662.76K Price14.55
Recom2.00 SMA20-1.22% SMA50-2.28% SMA200-33.95% Volume8,911 Change-3.71%
Sep-20-21 08:00AM  
Sep-13-21 08:00AM  
Sep-09-21 04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 08:00AM  
Jul-09-21 08:00AM  
Jul-01-21 04:00PM  
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.